Equillium/$EQ
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Equillium
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
Ticker
$EQ
Sector
Primary listing
Employees
35
Headquarters
Website
Equillium Metrics
BasicAdvanced
$130m
-
-$0.39
1.74
-
Price and volume
Market cap
$130m
Beta
1.74
52-week high
$2.70
52-week low
$0.27
Average daily volume
405k
Financial strength
Current ratio
10.579
Quick ratio
10.356
Long term debt to equity
1.245
Total debt to equity
2.514
Profitability
EBITDA (TTM)
-23.518
Management effectiveness
Return on assets (TTM)
-51.39%
Return on equity (TTM)
-93.99%
Valuation
Price to book
4.41
Price to tangible book (TTM)
4.41
Price to free cash flow (TTM)
-5.154
Free cash flow yield (TTM)
-19.40%
Free cash flow per share (TTM)
-0.398
Growth
Earnings per share change (TTM)
71.31%
3-year earnings per share growth (CAGR)
-40.45%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Equillium stock?
Equillium (EQ) has a market cap of $130M as of April 29, 2026.
What is the P/E ratio for Equillium stock?
The price to earnings (P/E) ratio for Equillium (EQ) stock is 0 as of April 29, 2026.
Does Equillium stock pay dividends?
No, Equillium (EQ) stock does not pay dividends to its shareholders as of April 29, 2026.
When is the next Equillium dividend payment date?
Equillium (EQ) stock does not pay dividends to its shareholders.
What is the beta indicator for Equillium?
Equillium (EQ) has a beta rating of 1.74. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.